| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
|
| | AG-L-5968 Basic information |
| Product Name: | AG-L-5968 | | Synonyms: | AG-L-5968;AG-L-59687;8-[2-Amino-6-[(4-bromo-2-thienyl)methoxy]-9H-purin-9-yl]octyl-alpha-D-glucopyranoside;AG-L 59687;AG-L59687;CS-280;α-D-Glucopyranoside, 8-[2-amino-6-[(4-bromo-2-thienyl)methoxy]-9H-purin-9-yl]octyl;O6BTG-C8-αGlu | | CAS: | 793035-88-8 | | MF: | C24H34BrN5O7S | | MW: | 616.53 | | EINECS: | | | Product Categories: | | | Mol File: | 793035-88-8.mol |  |
| | AG-L-5968 Chemical Properties |
| Boiling point | 847.4±75.0 °C(Predicted) | | density | 1.70 | | pka | 12.95±0.70(Predicted) |
| | AG-L-5968 Usage And Synthesis |
| Uses | O6BTG-C8-αGlu is an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor with an IC50 of 0.45 μM. At a concentration of 0.1 μM, O6BTG-C8-αGlu can completely inhibit MGMT in HeLaS3 cells. Even when applied chronically at high doses (up to 20 μM), it does not exhibit cytotoxicity. O6BTG-C8-αGlu is suitable for research on MGMT-related cancer diseases[1]. | | References | [1] Kaina B, et al. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther. 2004 Nov;311(2):585-93. DOI:10.1124/jpet.104.071316 |
| | AG-L-5968 Preparation Products And Raw materials |
|